IGC Pharma (IGC) Cash from Investing Activities (2010 - 2025)
IGC Pharma (IGC) reported Cash from Investing Activities of -$374000.0 for Q3 2025, down 475.38% year-over-year from $99631.1 in Q3 2024, and down 164.48% quarter-over-quarter from $580000.0 in Q2 2025.
IGC Pharma (IGC) Cash from Investing Activities (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has 16 years of Cash from Investing Activities data on file, last reported at -$374000.0 in Q3 2025.
- Cash from Investing Activities for Q3 2025 came in at -$374000.0, down 475.38% year-over-year; the trailing twelve-month figure through Sep 2025 was -$40000.0 (up 93.1% YoY), and the FY2026 annual result was -$170000.0, up 61.54% from the prior year.
- Cash from Investing Activities declined to -$374000.0 in Q3 2025 per IGC's latest filing, from $580000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $1.9 million in Q1 2021 and troughed at -$553000.0 in Q1 2022.
- A 5-year average of $20947.4 and a median of -$65000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities plunged 2520.0% in 2024, then soared 542.75% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$49000.0 in 2021, then jumped by 65.31% to -$17000.0 in 2022, then slumped by 258.82% to -$61000.0 in 2023, then plunged by 70.49% to -$104000.0 in 2024, then plunged by 259.62% to -$374000.0 in 2025.
- Business Quant data shows IGC's Cash from Investing Activities at -$374000.0 in Q3 2025, $580000.0 in Q2 2025, and -$142000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | IGC Pharma | 28.11 Mn | 27.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -374,000.00 |
| Sep 30, 2025 | -374,000.00 |
| Jun 30, 2025 | 580,000.00 |
| Jun 30, 2025 | 580,000.00 |
| Mar 31, 2025 | -142,000.00 |
| Mar 31, 2025 | -142,000.00 |
| Dec 31, 2024 | -104,000.00 |
| Dec 31, 2024 | -104,000.00 |
| Sep 30, 2024 | -65,000.00 |
| Sep 30, 2024 | -65,000.00 |
| Jun 30, 2024 | -131,000.00 |
| Jun 30, 2024 | -131,000.00 |
| Mar 31, 2024 | -323,000.00 |
| Mar 31, 2024 | -323,000.00 |
| Dec 31, 2023 | -61,000.00 |
| Dec 31, 2023 | -61,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -5,000.00 |